Showing 101-110 of 9358 results for "".
- Soligenix, Inc.’s SGX302 (Synthetic Hypericin) Demonstrates “Clear Biological Signal” in Phase 2a PsO Studyhttps://practicaldermatology.com/news/sgx302-synthetic-hypericin-demonstrates-clear-biological-signal-in-phase-2a-pso-study/2461854/Soligenix, Inc.’s SGX302 (synthetic hypericin) showed a clear biological signal in an initial five people with mild-to-moderate psoriasis, the company reports. Now, the study is expected to enroll at least an additional five subjects, exploring the use of SGX302 in the standard of care psoriasis s…
- One to Watch: AnaptysBio Inc.’s Imsidolimab (IL-36R) Shows Promise in GPPhttps://practicaldermatology.com/news/one-to-watch-imsidolimab-il-36r-shows-promise-in-gpp/2462052/AnaptysBio, Inc.’s Imsidolimab (IL-36R) performed well in in Generalized Pustular Psoriasis (GPP), according to topline results from the Phase 3 GEMINI-1 trial. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune…
- CeraVe Launches Two Skin Care Productshttps://practicaldermatology.com/news/20140123-cerave_launches_two_skin_care_products/2459361/CeraVe has introduced the CeraVe Eye Repair Cream and CeraVe Intensive Stretch Marks Cream. The Eye Repair Cream combines three essential ceramides, to help repair and restore the delicate barrier around the eyes, with hydrating hyaluronic acid to help diminish fine lines and wrinkles. The Intensiv…
- Meet Amber Edwards, Alastin Skincare’s New Chief Commercial Officerhttps://practicaldermatology.com/news/meet-amber-edwards-alastin-skincares-new-chief-commercial-officer/2460485/Amber Edwards is Alastin Skincare’s new Chief Commercial Officer, effective July 31, 2020 Ms. Edwards most recently served as President of North America for Sinclair Pharma. Prior to Sinclair, she was at Allergan, Inc. where she was the Vice President of International Strategic Marketing, Medical …
- Data Suggest Makucell's Asymmtate Reverses Gene Expression in Aging Skinhttps://practicaldermatology.com/news/20120725-makucell_announces_results_on_proprietary_technology_asymmtate/2459765/Makucell, Inc.'s Asymmtate(TM), the key ingredient in the Renewnt line, may reverse gene expression changes associated with aging skin and with lentigines. Findings for Asymmtate, a proprietary cosmetic ingredient that influences the gene co-activator choice used by ß-catenin to encourage skin stem…
- Mederma To Offer Products for Healthier Hair, Skin and Nailshttps://practicaldermatology.com/news/mederma-to-offer-products-for-healthier-hair-skin-and-nails/2458377/It’s not just scar and stretch mark reduction for Mederma anymore. Perhaps best known for such legacy products as scar gel and cream and stretch mark therapy, Mederma is now rolling out three new product lines for healthier hair, skin and nails. The Mederma team made the announcement at a media ev…
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like receptor (TLR)/i…
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick –and stretches and adhe…
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as p…
- Cutanea Life Sciences Launches Xepi Creamhttps://practicaldermatology.com/news/cutanea-life-sciences-launches-xepi-cream-1/2457512/Cutanea Life Sciences, Inc. has launched Xepi™ (ozenoxacin) Cream, 1% for the treatment of impetigo in adult and pediatric patients two months of age or older. Xepi is a non-fluorinated topical quinolone indicated for the treatment of impetigo due to Staphylococcus aureusand/or Streptococcus pyogen…